INNOVAX

Provide high quality and affordable vaccines to improve human well-being

Provide high quality and affordable vaccines to improve human well-being

<em>E.coli</em>-derived VLP platform, a scalable platform for next-generation vaccines

E.coli-derived VLP platform, a scalable platform for next-generation vaccines

Innovative vaccines including the world's only Hepatitis E vaccine and the world's second HPV vaccines

Innovative vaccines including the world's only Hepatitis E vaccine and the world's second HPV vaccines

State-of-the-art facilities supporting high-quality and scalable vaccine production

State-of-the-art facilities supporting high-quality and scalable vaccine production

Partnering globally to expand vaccine access through technology transfer

Partnering globally to expand vaccine access through technology transfer

Vaccine Business Headquarters of Wantai BioPharm

Xiamen Innovax Biotech Co., Ltd. (“IX”), founded in 2005, is one of China’s leading innovative vaccine companies engaged in the research, development, manufacturing, and commercialization of human vaccines.

Provide high quality and affordable vaccines to improve human well-being

Products

Provide high-quality and affordable vaccines to improve human well-being.

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Recombinant Hepatitis E Vaccine (Escherichia Coli)

The world's first and only Hepatitis E vaccine, supported by more than 10 years of real-world follow-up data on protective efficacy.

Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)

Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)

A WHO-prequalified bivalent HPV vaccine supported by more than 10 years of real-world follow-up data on protective efficacy.

Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (Escherichia coli)

Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (Escherichia coli)

Launched in 2025, Cecolin 9 offers protection against nine HPV types associated with cervical cancer and other HPV-related diseases.

Diverse Global Partnership Network

IX has established partnerships with healthcare institutions, government agencies, and international organizations across more than 30 countries and regions, accelerating the global reach of high-quality vaccines and empowering local vaccine manufacturing via technology transfer.

Angola

Angola

Angola selected Cecolin for first Introduction of HPV National Immunization Program in October 2025

Bangladesh

Burkina Faso

Belarus

Belarus

Belarus MoH introduced Cecolin to National EPI for 9 years old girls

Burundi

China

China

China grants approval for its first domestically developed 9-valent HPV vaccine Cecolin 9

Cambodia

Cuba

Cuba

Cuba implemented Cecolin vaccination to protect against human papillomavirus (HPV)

DR Congo

Egypt

Ethiopia

Ghana

Guatemala

India

India

Hecolin was successfully launched in India to help prevent hepatitis E virus infection

Indonesia

Kazakhstan

Kenya

Madagascar

Madagascar

Direction du Programme Elargi de Vaccination Msanp-Madagascar introduced Cecolin to National EPI for 9-14 years old of girls.

Mali

Mexico

Morocco

Myanmar

Nepal

Nepal

Nepal MoH introduced Cecolin to national EPI for 9-14 years old of girls

Nicaragua

Nicaragua

Nicaragua MoH introduced Cecolin to National EPI for 10-14 years old of girls

Niger

Nigeria

Pakistan

Pakistan

Pakistan MoH introduced Cecolin to National EPI for over 13 million 9-14 years old of girls in 3 provinces

Pakistan

Hecolin is approved and has been used in Pakistan, primarily in targeted or outbreak-related vaccination settings

South Sudan

SouthSudan

First large-scale hepatitis E vaccination campaign during an outbreak in a refugee camp in South Sudan

Thailand

Thailand

Thailand used Cecolin for National EPI and further expanded to 11-20 years old girls.

Tunisia

Sustainability

Guided by integrity, sustainability, and a long-term commitment to global public health.

Localization

Advancing local manufacturing, vaccine access and partnerships to strengthen the public health ecosystem.

Localization

Health Awareness

Promoting disease awareness and prevention through public health education and science-based information.

Health Awareness

Responsibility

Driving long-term value through responsible governance, ethical practices and sustainable development.

Responsibility

News

Stay updated on IX’s latest news, product milestones, research progress, and key events.

IX’s 9-valent HPV Vaccine Cecolin 9 Approved by Thai FDA

IX’s 9-valent HPV Vaccine Cecolin 9 Approved by Thai FDA

Recently, Xiamen Innovax Biotech Co., Ltd. (IX) announced that Cecolin 9, its 9-valent HPV vaccine jointly developed with Xiamen University, Thailand (Thai FDA). This approval not only establishes a solid ...

Xinhuanet highlights IX’s efforts to advance 9-valent HPV vaccine technology transfer in Indonesia

Xinhuanet highlights IX’s efforts to advance 9-valent HPV vaccine technology transfer in Indonesia

Phase III Clinical Data on Cecolin 9 Published in The Lancet Infectious Diseases

Phase III Clinical Data on Cecolin 9 Published in The Lancet Infectious Diseases

Delegation from the Consulate General of Pakistan in Guangzhou Visits IX to Explore New Opportunities in Innovative Vaccine Cooperation

Delegation from the Consulate General of Pakistan in Guangzhou Visits IX to Explore New Opportunities in Innovative Vaccine Cooperation

Cecolin 9 for Public Cecolin 9 for HCPs Vaccine Portfolio Contact Us Media Report an Adverse Event

Copyright © 2026 Xiamen Innovax Biotech Co., Ltd. All rights reserved. 闽ICP备05033276号-3

闽公网安备 35020502000554号 Terms of Use Privacy Policy